Why the study?
Does discontinuation of long-term risperidone treatment improve BMI and cardiometabolic outcomes in children and adolescents?
Population
101 medically healthy children and adolescents treated with risperidone for ≥6 months for mostly…
Comparison
Discontinuation of second-generation… vs Remaining on risperidone treatment (n=74)
Design
Cohort
Follow-up
1.5 years
Authors
Loading...
May support SGA discontinuation trials in overweight youth on risperidone; hypothesis-generating and requires RCTs before practice change.
Does discontinuation of long-term risperidone treatment improve BMI and cardiometabolic outcomes in children and adolescents?
Discontinuation of long-term risperidone in children and adolescents is associated with reversal of excessive weight gain and corresponding improvements in cardiometabolic parameters.
Calarge et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: